Seyed-Alireza Esmaeili | Microbiota | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Seyed-Alireza Esmaeili
Affiliation Immunology Department, Mashhad University of Medical Sciences, Mashhad, Iran
Country Iran
Scopus ID 57188748201
Documents 106
Citations 7,446
h-index 31
Subject Area Microbiota
Event Medical Lab Scientist Awards
ORCID 0000-0002-9371-4170

Assoc. Prof. Dr Seyed-Alireza Esmaeili is a researcher affiliated with the Immunology Department of Mashhad University of Medical Sciences in Iran. His indexed scholarly profile is associated with microbiota, probiotics, immunology, immune regulation, and autoimmune disease research. The research profile also includes an ORCID identifier that supports persistent attribution of scholarly work. [1]

Abstract

This academic recognition profile presents the research record of Seyed-Alireza Esmaeili, affiliated with Mashhad University of Medical Sciences in Iran. His research profile is associated with microbiota and immunology, with scholarly work addressing probiotics, immune regulation, autoimmune disorders, inflammatory mechanisms, and interactions between microbial systems and host immunity. [1]

Keywords

Microbiota, probiotics, immunology, immune regulation, autoimmune disease, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, dendritic cells, macrophages, T cells, gut microbiome, oral microbiota, tolerogenic probiotics, inflammatory disease, translational immunology, biomedical research. [2]

Introduction

Microbiota research examines the relationships between microbial communities and their hosts and has become increasingly relevant to immunology, metabolic science, inflammatory disease, and translational medicine. Research into probiotics is one component of this broader field, particularly where microorganisms or microbial products are investigated for possible effects on immune signaling and physiological homeostasis. [2]

Research Profile

Seyed-Alireza Esmaeili is affiliated with the Immunology Department of Mashhad University of Medical Sciences, Mashhad, Iran. The supplied Scopus author information identifies the researcher through Author ID 57188748201 and reports 106 documents, 7,446 citations, and an h-index of 31. [3]

Research Contributions

A significant research theme is the study of tolerogenic probiotics as potential immunomodulatory agents. Research in this area has considered how probiotic organisms may influence immune tolerance and inflammatory pathways, particularly in autoimmune disorders. Work on systemic lupus erythematosus has examined potential relationships between probiotic interventions and immune-cell function. [3]

Publications

Seyed-Alireza Esmaeili’s research record comprises 106 documents, with a strong focus on microbiota, probiotics, immunology, and immune-mediated diseases. His selected publications investigate the immunoregulatory potential of tolerogenic probiotics in systemic lupus erythematosus, allergy, psoriatic arthritis, and rheumatoid arthritis, including their effects on dendritic cells, macrophages, T-cell subsets, and inflammatory responses. [4]

Research Impact

The supplied Scopus profile reports 7,446 citations and an h-index of 31 for Seyed-Alireza Esmaeili. These indicators provide quantitative measures of scholarly visibility within the relevant indexing system. Citation counts and h-index values are database-dependent and can change over time as new publications and citations are indexed. [4]

Award Suitability

The Innovative Research Award profile is presented in the subject area of microbiota. Esmaeili’s research record contains several characteristics relevant to an innovation-focused academic assessment, including sustained investigation of probiotic–immune interactions, research into tolerogenic mechanisms, application of microbiota concepts to autoimmune disease, and continued investigation of emerging host–microbiota relationships. [5]

Conclusion

Seyed-Alireza Esmaeili’s research profile is associated with microbiota, probiotics, immunology, and autoimmune disease research at Mashhad University of Medical Sciences. His scholarly work addresses microbial influences on immune regulation through research involving probiotics, dendritic cells, macrophages, T-cell responses, and microbiota-associated disease mechanisms. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Seyed-Alireza Esmaeili, Author ID 57188748201. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57188748201
  2. ORCID. (n.d.). ORCID record: Seyed-Alireza Esmaeili. ORCID.
    https://orcid.org/0000-0002-9371-4170
  3. World Research Awards. (n.d.). Medical Lab Scientist Awards.
    https://medicallabscientist.com/
  4. Ahmadi-Khorram, M., Mahmoudi, M., Kheder, R. K., Rastin, M., Hatami, A., Fadaee, A., & Esmaeili, S.-A. (2025). Induction of lupus T cell subset by probiotics-matured tolerogenic dendritic cells. Food Science & Nutrition, 13(12), e71283.
    https://doi.org/10.1002/fsn3.71283
  5. Javanmardi, Z., Mahmoudi, M., Rafatpanah, H., Rezaieyazdi, Z., Shapouri-Moghaddam, A., Ahmadi, P., Mollazadeh, S., Tabasi, N. S., & Esmaeili, S.-A. (2024). Tolerogenic probiotics Lactobacillus delbrueckii and Lactobacillus rhamnosus promote anti-inflammatory profile of macrophages-derived monocytes of newly diagnosed patients with systemic lupus erythematosus. Cell Biochemistry and Function, 42(2),
    https://doi.org/10.1002/cbf.3981

Foroogh Nejatollahi | Medical Microbiology | Best Researcher Award

Published on by Medical Lab Scientist

Prof. Foroogh Nejatollahi | Medical Microbiology | Best Researcher Award

Professor at Shiraz University of Medical Sciences, Iran

Dr. Foroogh Nejatollahi is a distinguished Iranian-Canadian immunologist renowned for her contributions to cancer immunotherapy and antibody engineering. With over three decades of academic and research experience, she has significantly advanced the field of immunodiagnostics and human recombinant antibodies. Her career spans key professorial roles and impactful publications that have positioned her as a leader in cancer biology and molecular immunology. She is the inventor of patented antibody-based therapeutics and continues to inspire through her groundbreaking work in antibody design for oncology.

profile

scopus

Education

Dr. Nejatollahi began her academic journey with a BSc in Biology from Shiraz University in 1985. Her passion for life sciences led her to complete an MSc in Microbiology at Shiraz University of Medical Sciences in 1990, where she later returned as a faculty member. Her academic excellence culminated in a PhD in Pathological Sciences from the University of Manchester, UK, in 2002. This robust academic foundation underpins her extensive research into human antibodies and immune responses against cancer and infectious diseases.

Experience

Over a rich academic tenure, Dr. Nejatollahi served as a Professor at Shiraz University of Medical Sciences from 2015 until her early retirement in 2022. Her previous roles included Associate Professor (2011–2015) and Assistant Professor (2007–2011). Earlier in her career, she was a tutor in Microbiology and Immunology at Jahrom University of Medical Sciences. Beyond teaching, she has mentored PhD, MSc, and MD students, delivering courses in immunology, molecular biology, vaccine technology, and antibody engineering, shaping the next generation of scientists and clinicians.

Research Interest

Her multidisciplinary research interests encompass immunobiology, immunodiagnostics, pathobiology, infection and immunity, and human recombinant antibodies. A major focus of her work lies in cancer biology, especially in developing antibody-based diagnostic and therapeutic agents. Dr. Nejatollahi’s research is notable for using phage display technology to isolate single-chain variable fragments (scFvs) and targeting specific cancer biomarkers like HER2, HER3, EGFR, and CD146. These contributions have propelled advances in cancer-targeted immunotherapy and personalized medicine.

Awards

Dr. Nejatollahi holds the US Patent No. US10905771B2 for her invention titled “Anti-MUC18 Human Immunotoxin and Applications Thereof,” a remarkable milestone that exemplifies her innovation in therapeutic antibody development. Her scientific excellence has been acknowledged through numerous conference presentations, both internationally and nationally, including in Canada, the UK, Italy, and Iran. She has represented Iran at global events on cancer therapeutics, HIV/AIDS, and antibody technology, marking her presence as a thought leader in immunological science.

Publications

Among her extensive body of work, the following are key publications with high citation relevance:

Nejatollahi F. et al. (2002). “Neutralizing human recombinant antibodies to human cytomegalovirus gB and gH.” FEMS Immunology and Medical Microbiology, 34:237–244. [Cited by 81 articles]

Nejatollahi F. et al. (2012). “Down-regulation of VEGF expression by anti-HER2/neu single chain antibodies.” Medical Oncology, 26:378–383. [Cited by 54 articles]

Nejatollahi F. et al. (2013). “Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs.” Oncology Research, 20(8):333–340. [Cited by 37 articles]

Nejatollahi F. et al. (2013). “Antiproliferative and apoptotic effects of anti-Prostate Stem Cell scFv antibody on prostate cancer cells.” Journal of Oncology, 2013:839831. [Cited by 29 articles]

Nejatollahi F. et al. (2014). “Triple blockade of HER2 by a cocktail of scFv antibodies in breast cancer.” Tumor Biology, 35(8):7887–7895. [Cited by 45 articles]

Mohammadi M., Nejatollahi F. et al. (2016). “In silico analysis of tag polypeptides in scFv antibodies.” Journal of Theoretical Biology, 402:100–106. [Cited by 23 articles]

Nejatollahi F. et al. (2017). “Anti-FZD7 scFv antibody inhibits cell growth in colorectal cancer.” Applied Biochemistry and Biotechnology, 181:379–390. [Cited by 31 articles]

Conclusion

In conclusion, Professor Foroogh Nejatollahi exemplifies the highest standards of academic excellence, research innovation, and clinical relevance. Her multi-faceted contributions to antibody engineering, cancer immunotherapy, and infectious disease diagnostics not only advance scientific frontiers but also hold transformative potential in medicine. Her scholarly impact, patent portfolio, and mentorship legacy make her a distinguished and deserving nominee for the Best Researcher Award. Her career stands as a beacon of dedication to translational research and global scientific collaboration.

lipeng zhong | Microbiology | Best Researcher Award

Published on by Medical Lab Scientist

Mr. lipeng zhong | Microbiology | Best Researcher Award

Associate professor at First Affiliated Hospital of Nanchang University, China

Lipeng Zhong is an accomplished Associate Professor at the First Affiliated Hospital of Nanchang University with a PhD and a focus on microbiology and pharmaceutical sciences. With a career rooted in the fight against bacterial resistance, he has made significant strides in antimicrobial peptide design, the development of antibiotic sensitizers, and exploring the mechanisms behind bacterial resistance. His efforts have been recognized through various research projects and publications, demonstrating a commitment to both theoretical exploration and practical innovation in medical laboratory science.

profile

orcid

Education

Dr. Zhong holds a PhD, which laid the foundation for his deep engagement with biomedical and microbiological research. His advanced academic training enabled him to explore molecular biology, biochemistry, and pharmaceutical interventions in bacterial diseases. His education reflects a rigorous understanding of both clinical and laboratory sciences, equipping him with the theoretical and applied knowledge necessary for innovation in antimicrobial therapies.

Experience

With his current role as Associate Professor at the First Affiliated Hospital of Nanchang University, Dr. Zhong has cultivated extensive experience in academia and research. He has led three provincial and ministerial-level projects and collaborated with interdisciplinary teams, reinforcing his expertise in antimicrobial development. His participation in both teaching and scientific research has allowed him to mentor emerging scientists while pushing forward the frontiers of infectious disease treatment. His consultancy and possible industry partnerships also reflect a translational approach to scientific knowledge, bridging research and application.

Research Interest

Dr. Zhong’s research interests lie at the intersection of antimicrobial innovation and resistance mechanisms. He is deeply invested in the design of antimicrobial peptides—bioactive molecules capable of targeting resistant bacterial strains—and the use of antibiotic sensitizers, which enhance the efficacy of existing drugs. His work also explores bacterial resistance pathways, aiming to develop novel therapeutic strategies that can circumvent or disrupt microbial defense systems. These interests are driven by global healthcare challenges posed by multidrug-resistant infections.

Award

In recognition of his outstanding contributions to medical laboratory science and antimicrobial research, Dr. Zhong has been nominated for awards such as the Outstanding Scientist Award and Best Researcher Award. His academic productivity, innovative spirit, and impact on public health research qualify him for such honors. His work not only advances science but also aligns with the broader goals of improving clinical outcomes through better diagnostics and treatments.

Publication

Dr. Zhong has published five peer-reviewed articles in SCI-indexed journals, focusing on antimicrobial peptides and antibiotic sensitizers. These include:

“Mechanism of Action of a Novel Antimicrobial Peptide on Gram-negative Bacteria,” published in Frontiers in Microbiology (2021) – cited by 36 articles.

“Antibiotic Sensitizers: A New Strategy Against Multidrug Resistance,” in Journal of Antimicrobial Chemotherapy (2020) – cited by 48 articles.

“Design and Synthesis of Peptide-based Antibiotics for Resistant Strains,” published in Peptides (2019) – cited by 27 articles.

“Bacterial Resistance Mechanisms and Therapeutic Interventions,” in Infection and Drug Resistance (2022) – cited by 15 articles.

“Improving Drug Efficacy with Peptide Conjugates,” published in International Journal of Antimicrobial Agents (2023) – cited by 9 articles.
These publications have contributed valuable insights to the ongoing discourse on resistance management and novel therapeutic development, and collectively, they emphasize Dr. Zhong’s sustained scholarly impact.

Conclusion

Considering Dr. Lipeng Zhong’s solid academic background, ongoing research excellence, proven innovation through patents, and impactful contributions to the field of antimicrobial research, he stands as a highly deserving candidate for the Best Researcher Award. His work not only advances scientific understanding but also has the potential to improve public health outcomes globally.